News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vectura Group plc (VEC.L) to Present at Jefferies and Co. 2013 Global Healthcare Conference


5/29/2013 10:20:57 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Chippenham, UK 29th May 2013: Vectura Group plc ("Vectura"; LSE: VEC) announced today that Dr Chris Blackwell, Vectura’s Chief Executive Officer, is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Thursday, 6th June 2013, at 08:00 EDT. The conference will be held from 3rd – 6th June, 2013 at the The Grand Hyatt in New York City.

The presentation will be webcast live and can be reached from Vectura’s website at: http://www.vectura.com/investors/reports-presentations/2013.aspx

Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

Enquiries

Vectura Group plc +44 (0)1249 667700

Chris Blackwell, Chief Executive

Karl Keegan, Corporate Development Director

FTI Consulting +44 (0)20 7831 3113

John Dineen

About Vectura

Vectura Group plc and its subsidiaries (“Vectura” or the “Group”) is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airway diseases. This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $30 billion worldwide.

Vectura has seven products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK) and Tianjin King York Group Company Limited (KingYork).

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura’s formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura’s business strategy. For further information, please visit Vectura’s website at www.vectura.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES